← SynDRA
ABC-294640
SynDRA canonical compound SYN0033989 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | SPHK2 |
|---|
| Mechanism of action | Sphingosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Sphingosine kinase inhibitor
- SPHK2 INHIBITOR
- Sphingosine kinase 2 inhibitor
- angiogenesis inhibitor
- SPHK2 MODULATOR
Cross-references
Synonyms
- ABC 294640
- Opaganib
- Abc294640
- ABC294640
- CHEMBL2158685
- UNII-DRG21OQ517
- DRG21OQ517
- Yeliva
- SCHEMBL1548333
- GTPL6624
- CHEBI:124965
- MolPort-044-560-286
- HMS3402P05
- BCP08959
- EX-A1962
- BDBM50393642
- 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
- AKOS027327311
- CS-0877
- SB17167
- DB12764
- API0017247
- HY-16015
- S7174
- BRD-A70814879-003-01-8
- 4-pyridinylmethyl-3-(4-chlorophenyl) adamantane carboxamide
- 4-PYRIDINYLMETHYL 3(4-CHLOROPHENYL)ADAMANTINE CARBOXAMIDE
- opaganibum
- RefChem:856796
- SK2 inhibitor ABC294640
- DTXCID801748526
- MFCD22666355
- OPAGANIB [INN]
- ABC294640Opaganib?
- OPAGANIB [WHO-DD]
- Opaganib (ABC294640)
- orb1300500
- NSC796101
- CCG-268417
Look up ABC-294640 in the interactive SynDRA portal →